IL13RA2 and glioblastoma: Several other early phase I and I/II studies evaluating single tumor antigen pulsed DCs have similarly shown minimal overall toxicity and paucity of CNS neurotoxicity (Table 1) including a phase I trial for recurrent GBM I which patients received DCs pulsed with WT1 (72, 73) and a phase I trial of IL-13Ra2 pulsed DCs (74).